Efficient Biological Drug Development Workflows: Lead Candidate to Drug Substance
Tags: Early Discovery
Discover how to support a faster critical development path and reduce timelines to manufacture of drug substance and product for clinical trials with strategies for maximizing the overlap of activities during process development and manufacture, keeping DC selection options open for longer to generate better data with the aim of minimising risk.
The discussion explores how the use of small-scale, analogous early material production from stable CHO pools can be employed to unearth potential issues in biological products allowing for better decisions during DC selection and informing process design and control strategies.
Access the full on-demand webinar from our team of industry experts as they take an in-depth look at their area of specialism.
You may also be interested in...
Pre-formulation: De-risking Development Programs to Ensure a Successful IND Filing.
Discover how to streamline your drug programs by better-utilising pre-formulation programmes and see how Abzena approaches pre-formulation to identify fundamental drug properties.
Watch the Webinar
Collaborative Approaches Needed to Effectively Speed Up and Streamline Development.
Listen to the strategies used to effectively speed up and streamline development including insight into the collaborative approaches needed between functional areas and the compromises required.
Watch the Webinar
The Strategy Behind Your Journey to GMP with Emphasis on Linker Payload Development.
Develop lower risk strategies with our insights into the key considerations you need to factor in when conjugating your linker payload to its antibody in our review of the pros and cons of semi-synthetic and synthetic linker payloads.
Watch the Webinar